SCHEMBL13006497

SCHEMBL13006497

c1ccc(-c2cc(-c3cc(-c4cccc(-n5c6ccccc6c6cnccc65)n4)cc(-c4ccccn4)n3)cc(-c3ccccc3)n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TGFBR1 P36897 1/20 0.39
▸ METAP1 P53582 3/20 0.36
▸ CYP19A1 P11511 1/20 0.36
▸ MAOA P21397 4/20 0.36
▸ MAOB P27338 4/20 0.36
▸ MAPK1 P28482 3/20 0.36
▸ LMNA P02545 2/20 0.36
▸ ACHE P22303 1/20 0.36
▸ MAPT P10636 1/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ CCR1 P32246 2/20 0.35
▸ CCR5 P51681 2/20 0.35
▸ CCR8 P51685 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ ALPL P05186 1/20 0.35
▸ HSP90AA1 P07900 1/20 0.35
▸ ALPI P09923 1/20 0.35
▸ ALPG P10696 1/20 0.35
▸ ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13006391 1.00 TGFBR1 (0.39) TGFBR1METAP1CYP19A1MAOAMAOB
SCHEMBL13006389 0.93 CYP19A1 (0.39) TGFBR1METAP1CYP19A1MAOAMAOB
SCHEMBL3392504 0.92 CYP19A1 (0.39) TGFBR1METAP1CYP19A1MAOAMAOB
SCHEMBL3394813 0.92 CYP19A1 (0.39) TGFBR1METAP1CYP19A1MAOAMAOB
SCHEMBL12756926 0.91 MAPT (0.40) TGFBR1METAP1MAOAMAOBMAPK1
SCHEMBL13006482 0.91 CYP19A1 (0.40) TGFBR1METAP1CYP19A1MAOAMAOB
SCHEMBL13006547 0.90 CCR1 (0.39) TGFBR1CYP19A1MAOAMAOBMAPK1
SCHEMBL13006563 0.90 CCR1 (0.41) TGFBR1METAP1MAOAMAOBMAPK1
SCHEMBL13006418 0.90 MCL1 (0.40) CYP19A1MAOAMAOBMAPK1LMNA
SCHEMBL3392129 0.90 TNF (0.39) TGFBR1MAOAMAOBMAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2246351-B1 COMPOUND HAVING PYRIDOINDOLE RING STRUCTURE BONDED WITH SUBSTITUTED PYRIDYL GROUP, AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO LTD (JP) 2015-05-06 — — EP disclosed
US-8624228-B2 Compound having pyridoindole ring structure bonded with substituted pyridyl group, and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2014-01-07 — — US disclosed
US-8624228-B2 Compound having pyridoindole ring structure bonded with substituted pyridyl group, and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2014-01-07 — — US disclosed
US-20100308322-A1 COMPOUND HAVING PYRIDOINDOLE RING STRUCTURE BONDED WITH SUBSTITUTED PYRIDYL GROUP, AND ORGANIC ELECTROLUMINESCENT DEVICE Hodogaya Chemical Co,. Ltd. (JP) 2010-12-09 — — US disclosed
US-20100308322-A1 COMPOUND HAVING PYRIDOINDOLE RING STRUCTURE BONDED WITH SUBSTITUTED PYRIDYL GROUP, AND ORGANIC ELECTROLUMINESCENT DEVICE Hodogaya Chemical Co,. Ltd. (JP) 2010-12-09 — — US disclosed
EP-2246351-A1 COMPOUND HAVING PYRIDOINDOLE RING STRUCTURE BONDED WITH SUBSTITUTED PYRIDYL GROUP, AND ORGANIC ELECTROLUMINESCENT DEVICE Hodogaya Chemical Co., Ltd. (JP) 2010-11-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100308322-A1 COMPOUND HAVING PYRIDOINDOLE RING STRUCTURE BONDED WITH SUBSTITUTED PYRIDYL GROUP, AND ORGANIC ELECTROLUMINESCENT DEVICE KCNH3, KCNH2, PRDM9 TGFBR1 337/4885METAP1 4452/4885CYP19A1 999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback